GDC 0853

Drug Profile

GDC 0853

Alternative Names: Bruton’s tyrosine kinase inhibitor - Genentech; GDC-0853; RG 7845; RO 7010939

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Autoimmune disorders
  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Dec 2016 Genentech initiates an extension phase II trial for Rheumatoid arthritis (Adjunctive treatment, Treatment-experienced) in USA (PO, Tablet) (NCT02983227)
  • 14 Sep 2016 Genentech plans a phase II trial for Systemic lupus erythematosus in USA, Argentina, Brazil, Bulgaria, Chile, Colombia, France, South Korea, Mexico, Spain, Thailand and United Kingdom (NCT02908100)
  • 01 Jul 2016 Phase-II clinical trials in Rheumatoid arthritis (Adjunctive treatment, Treatment-experienced) in USA (PO, Tablet) (NCT02833350)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top